Federal grant · project grant (b)
Highly Sensitive Immunoassay for Determination of Biomarkers for Neurodegenerative Diseases - Abstract the Long-term Objective of This Proposal Is to Further Develop a Photochemical Signal Amplification Method (PSAM) for Increasing the Sensitivity of Conventional Enzyme-linked Immunosorbent Assays (ELISA) for Determination of Biomarkers for Various Neurodegenerative Diseases, Such as Alzheimer’s Disease (ad). Immunoenzymatic Methods Such as Elisa Are Widely Used in Biology and Medicine for Drug Screening, for Detecting Viruses (including Coronaviruses), Bacteria, and Biomarkers, Particularly Cytokines and Interleukins for Cancer and Immunological Disorders, and Biomarkers for Neurodegenerative Diseases. They Are Routinely Used in Manual, Semi-automated, and Automated Systems Where High Volumes of Tests Are Performed. However, in Many Cases the Sensitivity of Elisa Is Inadequate. Some of the Key Biomarkers for Early Diagnosis of Ad Include Three Cerebrospinal Fluid (CSF) Biomarkers: Amyloid SS-42 (ASS-42), Which Causes Formation of Oligomeric Plaques, Total Tau (t-tau), and Phosphorylated Tau (p-tau) (which Increases Intracellular Neurofibrillary Tangles (NFTS). to Date, There Is No Sensitive and Cost- Effective Method for the Quantification of These Three Proteins, Hindering the Diagnosis and Progression Monitoring of Ad. Existing Highly Sensitive Methods Are Cumbersome and Expensive. Therefore, There Is an Increased Necessity for a Common Elisa Platform to Detect Low Levels of ASS-42, T-tau, P-tau and Other Biomarkers for Various Neurodegenerative Diseases That Is Both Inexpensive and Simple Enough to Not Require Specialized Laboratory Equipment. in Our Phase I Project, We Propose to Further Develop a Very Sensitive and Inexpensive Immunoassay Platform for Detection of Biomarkers for Various Neurodegenerative Diseases. the Proposed Technology, Elisa + Psam, Consists of Two Steps: (1) a Conventional Horseradish Peroxidase (hrp)-mediated Assay (ELISA) in Which a Common Chromogenic HRP Substrate, Is Used and (2) a Substrate Solution Containing the Product of the Enzymatic Reaction Is Irradiated by Visible Light. Illumination of the Sample Leads to a Dap- Catalyzed Drastic Increase in Dap Concentration (autocatalytic Photochemical Reaction). the Specific Aims of Phase I Are: 1. to Explore All Variables Affecting the Performance of Elisa + Psam Assays for Detection of ASS-42, T-tau and P-tau and Optimize the Performance of the Assays. to Develop a Universal Approach for Transitioning From Elisa to Elisa + Psam Assays. 2. to Validate the Universal Approach for Optimization of Elisa + Psam Assays by Using Up to 3 Commercially Available Elisa Kits From Different Manufacturers for Each Analyte. This Will Include Determination of Sensitivity and Reproducibility/precision of the Assays.
Committed
$457,155
Paid out
$387.9K
85%
Committed, not yet paid
$69.3K
15%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.